Valiant Laboratories Ltd. (IN:VALIANTLAB)
:VALIANTLAB
Want to see IN:VALIANTLAB full AI Analyst Report?
VALIANTLAB Stock Chart & Stats
₹73.50
-₹2.57(-2.33%)
At close: 4:00 PM EST
₹73.50
-₹2.57(-2.33%)
Day’s Range― - ―
52-Week Range₹47.60 - ₹114.72
Previous CloseN/A
Volume41.92K
Average Volume (3M)1.58K
Market Cap
₹3.69B
Enterprise Value₹4.01B
Total Cash (Recent Filing)₹629.06M
Total Debt (Recent Filing)₹537.68M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthModest leverage and a sizeable equity base provide a durable financial cushion. This reduces short-term refinancing risk, supports working capital needs and strategic investments, and gives management flexibility to manage cash burn or pursue opportunistic growth over the next several months.
Revenue RecoveryA strong top-line rebound indicates underlying demand resilience in core API sales and the company’s ability to regain lost volumes. Sustained revenue growth supports operational leverage and the potential to rebuild margins and cash flow if the trend persists over the 2–6 month horizon.
Durable Business Model (APIs)API and bulk-drug manufacturing serves as an essential, repeatable part of the pharma supply chain with recurring contract and toll-manufacturing demand. This structural position supports steadier revenue streams and long-term customer relationships versus one-off product sales.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow indicate the business is burning cash or consuming capital for investment/working capital. Over months this increases reliance on external funding, constrains reinvestment, and heightens liquidity and solvency risk if operating cash conversion does not improve.
Current Unprofitability / Near‑Break‑Even EBITTurning from multi-year profits to losses, and reporting near-zero operating profit despite revenue recovery, suggests structural margin pressure or elevated costs. Without durable margin improvement, the company will struggle to convert sales into sustainable earnings and generate free cash flow.
Volatile Returns On CapitalLarge swings in ROE and profitability point to execution, demand, or cost-cycle volatility. This unpredictability undermines confidence in consistent returns, complicates capital allocation and strategic planning, and raises investor risk over the medium term.
Valiant Laboratories Ltd. News
VALIANTLAB FAQ
What was Valiant Laboratories Ltd.’s price range in the past 12 months?
Valiant Laboratories Ltd. lowest stock price was ₹47.60 and its highest was ₹114.72 in the past 12 months.
What is Valiant Laboratories Ltd.’s market cap?
Valiant Laboratories Ltd.’s market cap is ₹3.69B.
When is Valiant Laboratories Ltd.’s upcoming earnings report date?
Valiant Laboratories Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 55 days.
How were Valiant Laboratories Ltd.’s earnings last quarter?
Valiant Laboratories Ltd. released its earnings results on May 14, 2026. The company reported ₹0.32 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.32.
Is Valiant Laboratories Ltd. overvalued?
According to Wall Street analysts Valiant Laboratories Ltd.’s price is currently Overvalued.
Does Valiant Laboratories Ltd. pay dividends?
Valiant Laboratories Ltd. does not currently pay dividends.
What is Valiant Laboratories Ltd.’s EPS estimate?
Valiant Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valiant Laboratories Ltd. have?
Valiant Laboratories Ltd. has 54,312,500 shares outstanding.
What happened to Valiant Laboratories Ltd.’s price movement after its last earnings report?
Valiant Laboratories Ltd. reported an EPS of ₹0.32 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.028%.
Which hedge fund is a major shareholder of Valiant Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VALIANTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valiant Laboratories Ltd.
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in various grades that meet Indian, British, European, and United States pharmacopoeia standards. This crucial compound is utilized in treatments for common ailments such as headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. Beyond pharmaceuticals, the company also supplies specialty chemicals. Originally established in 1980 and headquartered in Mumbai, India, the firm rebranded as Valiant Laboratories Limited in August 2021, having previously operated under the name Bharat Chemicals. It functions as a subsidiary of Dhanvallabh Ventures LLP.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Medicamen Biotech Limited
―
Medico Remedies Ltd.
―
Zim Laboratories Ltd.
―